

**Trellus Health plc**  
("Trellus Health", the "Company" or the "Group")

**Contract signed with second leading CRO**

**LONDON, U.K. AND NEW YORK, U.S. (07 November 2025)** Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has signed a 12 month contract (the "Contract") with one of the largest global clinical research organisations ('CRO's') to utilise its Trellus TrialSet™ offering. The Contract is due to commence before year end, and will focus on immunology and inflammation, supporting recruitment and enrolment optimisation for two late-stage clinical trials.

This marks the Company's second contract with a leading CRO, further reinforcing the clinical trials sector as a strategic growth area for Trellus Health®. The Trellus TrialSet™ program is designed to enhance clinical trial recruitment by identifying individuals with lower resilience who may be hesitant to enrol and providing structured, evidence-based support to strengthen their resilience and readiness for participation.

The Contract, which includes an upfront fee, a monthly management fee, and milestone payments, is structured around three key performance indicators: (i) the number of potential eligible participants opting into the Trellus TrialSet™ program, (ii) the increase in qualified participants referred for screening, and (iii) the reduction in the screen failure rate.

**Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:** *"This represents another important milestone for Trellus Health®, underscoring the intrinsic value of our Trellus TrialSet™ digital solution and reflecting our continued focus on strategic execution. Since its launch earlier this summer, we have entered into two agreements with leading CROs, validating the relevance and differentiation of our offering. While the contract does not immediately extend the Company's current cash runway beyond early December 2025, combined with the Patient Support Program agreement signed with Johnson & Johnson in January 2025 which launched in the spring, these milestones demonstrate the growing recognition of the value Trellus Health delivers to the pharmaceutical sector."*

*"The Company continues to explore options for a potential equity fundraising and further updates will be provided in due course, as appropriate."*

**Regulatory Information**

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

**Enquiries:**

**Trellus Health plc**

<https://trellushealth.com/>

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder  
Joy Bessenger, Chief Financial Officer

**Via Walbrook PR**

**Singer Capital Markets**

Jen Boorer / James Todd / Patrick Weaver

Tel: +44 (0)20 7496 3000

**Walbrook PR**

Paul McManus / Lianne Applegarth /

Tel: +44 (0)20 7933 8780 or [trellus@walbrookpr.com](mailto:trellus@walbrookpr.com)  
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/

**About Trellus Health plc ([www.trellushealth.com](http://www.trellushealth.com))**

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic, costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement.

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: [www.trellushealth.com](http://www.trellushealth.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTUPGWWGUPAGMQ